Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Almuth F Kessler

Showing results (11-20 of 36) with videos related to

Pageof 4
Sort By:
Pharmaceutics|January 21, 2023
Tumor Treating Fields (TTFields) Induce Cell Junction Alterations in a Human 3D In Vitro Model of the Blood-Brain BarrierEllaine Salvador, Theresa Köppl, Julia Hörmann, et al.
Cancers|May 1, 2020
Ribosomal Protein S27/Metallopanstimulin-1 (RPS27) in Glioma-A New Disease Biomarker?Jonas Feldheim, Almuth F Kessler, Dominik Schmitt, et al.
Oncotargets and Therapy|December 26, 2018
Expression of activating transcription factor 5 (ATF5) is increased in astrocytomas of different WHO grades and correlates with survival of glioblastoma patientsJonas Feldheim, Almuth F Kessler, Dominik Schmitt, et al.
Oncotarget|March 9, 2018
CXCR4: A new player in vestibular schwannoma pathogenesisMaria Breun, Alexandra Schwerdtfeger, Donato Daniel Martellotta, et al.
Cancers|November 11, 2022
Glioblastoma-Derived Three-Dimensional Ex Vivo Models to Evaluate Effects and Efficacy of Tumor Treating Fields (TTFields)Vera Nickl, Ellina Schulz, Ellaine Salvador, et al.
Cancers|June 10, 2023
BRMS1 in Gliomas-An Expression AnalysisJonas Feldheim, Almuth F Kessler, Julia J Feldheim, et al.
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine|August 16, 2014
Comparison of the amino acid tracers 18F-FET and 18F-DOPA in high-grade glioma patientsConstantin Lapa, Thomas Linsenmann, Camelia Maria Monoranu, et al.
Cancers|June 16, 2019
Circulating MACC1 Transcripts in Glioblastoma Patients Predict Prognosis and Treatment ResponseCarsten Hagemann, Nikolas Neuhaus, Mathias Dahlmann, et al.
Journal of Neurology, Neurosurgery, and Psychiatry|April 30, 2018
O-(2-(<sup>18</sup>F)fluoroethyl)-L-tyrosine PET for the differentiation of tumour recurrence from late pseudoprogression in glioblastomaMilena I Mihovilovic, Olivia Kertels, Heribert Hänscheid, et al.
Molecular Imaging and Biology|April 13, 2019
Prognostic Value of O-(2-[<sup>18</sup>F]Fluoroethyl)-L-Tyrosine PET/CT in Newly Diagnosed WHO 2016 Grade II and III GliomaOlivia Kertels, Almuth F Kessler, Milena I Mihovilovic, et al.
Pageof 4

Showing results (11-20 of 36) with videos related to

Sort By:
Pageof 4
Pharmaceutics|January 21, 2023
Tumor Treating Fields (TTFields) Induce Cell Junction Alterations in a Human 3D In Vitro Model of the Blood-Brain BarrierEllaine Salvador, Theresa Köppl, Julia Hörmann, et al.
Cancers|May 1, 2020
Ribosomal Protein S27/Metallopanstimulin-1 (RPS27) in Glioma-A New Disease Biomarker?Jonas Feldheim, Almuth F Kessler, Dominik Schmitt, et al.
Oncotargets and Therapy|December 26, 2018
Expression of activating transcription factor 5 (ATF5) is increased in astrocytomas of different WHO grades and correlates with survival of glioblastoma patientsJonas Feldheim, Almuth F Kessler, Dominik Schmitt, et al.
Oncotarget|March 9, 2018
CXCR4: A new player in vestibular schwannoma pathogenesisMaria Breun, Alexandra Schwerdtfeger, Donato Daniel Martellotta, et al.
Cancers|November 11, 2022
Glioblastoma-Derived Three-Dimensional Ex Vivo Models to Evaluate Effects and Efficacy of Tumor Treating Fields (TTFields)Vera Nickl, Ellina Schulz, Ellaine Salvador, et al.
Cancers|June 10, 2023
BRMS1 in Gliomas-An Expression AnalysisJonas Feldheim, Almuth F Kessler, Julia J Feldheim, et al.
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine|August 16, 2014
Comparison of the amino acid tracers 18F-FET and 18F-DOPA in high-grade glioma patientsConstantin Lapa, Thomas Linsenmann, Camelia Maria Monoranu, et al.
Cancers|June 16, 2019
Circulating MACC1 Transcripts in Glioblastoma Patients Predict Prognosis and Treatment ResponseCarsten Hagemann, Nikolas Neuhaus, Mathias Dahlmann, et al.
Journal of Neurology, Neurosurgery, and Psychiatry|April 30, 2018
O-(2-(<sup>18</sup>F)fluoroethyl)-L-tyrosine PET for the differentiation of tumour recurrence from late pseudoprogression in glioblastomaMilena I Mihovilovic, Olivia Kertels, Heribert Hänscheid, et al.
Molecular Imaging and Biology|April 13, 2019
Prognostic Value of O-(2-[<sup>18</sup>F]Fluoroethyl)-L-Tyrosine PET/CT in Newly Diagnosed WHO 2016 Grade II and III GliomaOlivia Kertels, Almuth F Kessler, Milena I Mihovilovic, et al.
Pageof 4